A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance - Takeaways - MDSpire
Advertisement
A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance
Approximately 3% to 4% of the population over the age of 50 is diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It carries a lifelong risk of progression to multiple myeloma and lymphoma, requiring risk-adapted monitoring by multidisciplinary teams.
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic condition characterized by monoclonal proteins in plasma or urine.
2
MGUS is prevalent in 3% to 4% of individuals over 50 and can progress to smoldering multiple myeloma or active multiple myeloma.
3
Ms. Jones, a 54-year-old with IgA lambda MGUS, has a 37% risk of progression to multiple myeloma over 20 years, reduced to 18% considering competing mortality.
4
The PANGEA model indicates Ms. Jones has a 2.5% risk of progression to multiple myeloma in 2 years and 7% in 5 years, guiding her monitoring strategy.
5
MGUS requires ongoing observation, with advanced practice providers equipped to manage and monitor patients effectively.
